G2 arrest of cells suffering DNA damage in S phase is crucial to avoid their entry into mitosis, with the concomitant risks of oncogenic transformation. According to the current model, signals elicited by DNA damage prevent mitosis by inhibiting both activation and nuclear import of cyclin B1-Cdk1, a master mitotic regulator. We now show that normal human fibroblasts (NHF) use additional mechanisms to block activation of cyclin B1-Cdk1.
Introduction
Cyclin B1-Cdk1 is a master mitotic regulator and is therefore an ultimate target towards which most, if not all, anti-proliferative signals generated during S and G2 phase converge. In cycling cells, cyclin B1 synthesis increases during late S-early G2 phase (Pines and Hunter, 1989) but the newly formed cyclin B1-Cdk1 complexes are kept inactive by inhibitory phosphorylations on Thr 14 and Tyr 15 (Norbury et al., 1991) and by active and constant nuclear exclusion via Crm1-mediated nuclear export (Hagting et al., 1998; Yang et al., 1998) . The rapid nuclear accumulation of cyclin B1-Cdk1 that occurs in prophase coincides with phosphorylation of cyclin B1 at the cytoplasmic retention sequence (CRS) which contains also its nuclear export sequence (NES; (Hagting et al., 1999) rev. in (Porter and Donoghue, 2003) . Nuclear import of cyclin B1-Cdk1 coincides with Cdc25 phosphatase-mediated dephosphorylation of Thr 14 and Tyr 15 on Cdk1 (Berry and Gould, 1996) . Based on these observations, it has been assumed that cytoplasmic cyclin B1-Cdk1 is not active. However, both earlier and most recent work suggest that cyclin B1-Cdk1 might already be activated in the cytoplasm, and most probably at the centrosome (Heald et al., 1993; De Souza et al., 2000; Hirota et al., 2003; Jackman et al., 2003) .
According to the current model, signals elicited by DNA damage in S and G2 phases prevent mitotic entry by inhibiting both activation (via inactivation of Cdc25) and nuclear import of cyclin B1-Cdk1 (Jin et al., 1998; Yang et al., 1998; Deming et al., 2001; Yang et al., 2001 ). G2 arrest is initiated via phosphorylation of Cdc25 by Chk1/2 kinases, a process that does not require active p53. On the other hand, the maintenance of G2 arrest is highly p53-dependent and involves at least two of its transcriptional targets, the Cdk inhibitor p21 Waf1/Cip1 (p21) and the adaptor protein 14-3-3σ (for reviews see ref. (Ohi and Gould, 1999; Taylor and Stark, 2001 ). The latter protein has been proposed to mediate nuclear exclusion of cyclin B1-Cdk1, an event thought to be necessary for blocking mitosis (Chan et al., 1999; van Hemert et al., 2001) .
Despite accumulating evidence suggesting that p21 could regulate DNA damageinduced G2 arrest (Bunz et al., 1998; Dulic et al., 1998; Winters et al., 1998; Chan et al., 2000; Flatt et al., 2000; Baus et al., 2003) , it is widely assumed that this inhibitor does not play a direct role in inactivating mitotic cyclin-Cdk1 complexes, partly because of its low affinity toward Cdk1 (Harper et al., 1995) . Indeed, p21 has been detected only in a minority of cyclin B1-Cdk1 complexes after DNA damage (Levedakou et al., 1995; Barboule et al., 1999; Flatt et al., 2000) or even after overexpression of p53 or p21 (Winters et al., 1998; Smits et al., 2000) . This is in striking contrast to another mitotic regulator, cyclin A-Cdk1, which massively associates with p21 in response to DNA damage suggesting that, at least in normal human fibroblasts (NHF), Cdk1 could be a major target of this inhibitor (Dulic et al., 1998; Baus et al., 2003) . Moreover, it has been shown that overexpression of p21 might block phosphorylation of Cdk1 on Thr 161 by CAK (Smits et al., 2000) or even promote nuclear accumulation of cyclin B1 in the absence of mitotic events (Winters et al., 1998; Smits et al., 2000) . However, these observations made in transformed or immortalized cell lines, are difficult to reconcile with the current model according to which DNA damage-induced G2 arrest is accomplished by nuclear exclusion of cyclin B1-Cdk1.
In this paper we investigate whether in normal human fibroblasts p21 plays a direct role in controling cellular distribution and activation of cyclin B1-Cdk1 in response to genotoxic stress.
Materials and Methods
Cell culture, treatment and synchronization. Normal human foreskin fibroblasts (NHF) as well as NHF expressing HPV-16 E6 or E7 oncogenes were described previously . The cells were cultured in DMEM supplemented with 10% FCS. Wildtype and p21(-/-) human lung fibroblasts (LF1) were cultured in special hypoxic conditions as described earlier (Wei et al., 2001) .
Drug concentrations and synchronisation protocols were as described . Cells were pre-synchronized by contact inhibition, replated (1/4 dilution) to stimulate cell cycle entry and synchronized at the G1/S boundary by incubation with 2 mM hydroxyurea (10-12 hours). The drugs were added 2 hours after release from the G1/S block. Control cells were fixed in methanol 26 hours after replating at the time when most control cells had entered mitosis. ICRF-193-treated cells were fixed three hours later. The cell cycle distribution was determined by flow cytometric analysis (FACS) of propidium iodide-stained cells. In some experiments (Figures 2, 5, 6 and 7), drugs were added to asynchronously proliferating cultures as described previously .
Where indicated (Figure 4 , Suppl. Figure 2) cells were irradiated (8 Gy) using a 137 Cesium source and fixed for immunofluorescence experiments 12 hours later.
Immunofluorescence microscopy. The conditions for cell fixation, doubleimmunolabeling and mounting were as described previously (Dulic et al., 1998) . To detect cyclin B1, γ-tubulin and Mpm2, the cells were fixed in methanol at -20°C. Primary antibodies to cyclin B1 (monoclonal GNS1, sc-245 and polyclonal sc-752) and polyclonal antibody to p21 (sc-397) were from Santa-Cruz Biotechnology, polyclonal and monoclonal anti-γ-H2AX antibodies and monoclonal anti-Chk2 antibody were from Upstate Biotechnology, and monoclonal antibody to Mpm2 and γ-tubulin were purchased from DAKO Corporation and Sigma, respectively. Antibodies specific to phosphorylated cyclin B1 (P-S133 and P-S126) were generous gifts of Drs. M. Jackman and J. Pines (Jackman et al., 2003) . Other antibodies used were described previously (Dulic et al., 1998; Baus et al., 2003) .
Immunofluorescence and phase contrast photomicrographs were image-captured and a composite generated using Adobe Macintosh Photoshop or Microsoft Powerpoint softwares.
Immunobiochemistry. Preparation of whole cell lysates from frozen cell pellets, conditions for immunoprecipitation of cyclin complexes, p21 immunodepletion experiments, histone H1 kinase assays and immunoblotting as well as all the primary and secondary antibodies used in those experiments have been described previously (Dulic et al., 1998; Baus et al., 2003) . Secondary antibodies for western blot analysis were antimouse-IgG-HRP (DAKO corporation), anti-rabbit IgG HRP-conjugates (Promega) and protein A/G coupled to HRP (Pierce). Proteins were visualised by ECL according to manufacturer protocol (Amersham).
Recombinant Cdc25B, a gift of Dr. Véronique Baldin (CRBM), was prepared and assayed as described previously (Cans et al., 1999) .
Results

DNA damage induces pre-mitotic cyclin B1 nuclear accumulation
Our previous work showed that, in response to DNA damage-inducing agents during S phase, normal human fibroblasts (NHF) arrest in G2 accumulating inactive cyclin A-Cdk and cyclin B1-Cdk complexes . This cell cycle arrest was accompanied by strong accumulation of p21 and its association with both Cdk2 and Cdk1.
Even though cyclin A-Cdk1/2 complexes were major targets of p21, we repeatedly observed a significant fraction of cyclin B1-Cdk1 complexes that was associated with this inhibitor . To better understand the role of this latter interaction, we followed by immunofluorescence the localisation of p21 and cyclin B1 in synchronised NHF that were specifically arrested in G2 phase in the presence of ICRF-193 (Suppl. Figure 1a) , a catalytic inhibitor of DNA topoisomerase II (Roca et al., 1994) . Although earlier reports proposed that ICRF-193 does not induce double DNA strand breaks (Downes et al., 1994) , distinct nuclear γ-H2AX foci (Rogakou et al., 1999) could be detected in drug-treated cells (Suppl. Figure 2A) , thus confirming recent observations (Mikhailov et al., 2002) . Moreover, exposure to ICRF-193 induced activation of the checkpoint kinase Chk2, and this occurred regardless of the status of p53 or pRb, as documented by the appearance of an SDS-PAGE mobility shift (Suppl. Figure 2B ).
After treatment with ICRF-193, a large population of cells accumulated cyclin B1 in the nucleus without apparent chromosome condensation ( Figure 1A and Figure 3B for statistics). Moreover, and in contrast to control G2/M cells (our unpublished results), drugtreated cells invariably contained high p21 levels ( Figure 1A) . To assure that these cells were effectively blocked in G2, we determined their cell cycle status with more accuracy using the Mpm2-specific antibody (Davis et al., 1983; Westendorf et al., 1994) . In contrast to the signal obtained with the widely used antibody directed against phospho-histone H3 Thus, this stage would correspond to "antephase" or "transition 1", the terms used previously to describe late G2 phase (Pines and Rieder, 2001 According to the Mpm2 signal and the centrosomal status, most of the ICRF-193-treated cells accumulating nuclear cyclin B1 appeared to be arrested in late G2 phase, prior to stage 1 ( Figure 1B) . However, a precise cell cycle stage could not be assigned to these cells, since their equivalent could not be observed in an untreated, asynchronously growing population. Note that, unlike untreated cells, where centrosomal cyclin B1 signal strongly increased before nuclear accumulation in early prophase (arrows in Figure 1B ), in drug-arrested cells cyclin B1-associated staining of this organelle was much weaker (Figure 1B and C) . Indeed, an antibody raised against phosphorylated Ser133 of cyclin B1 (PS133), which recognizes the cyclin B1-Cdk1 complex activated by Plk1 at centrosomes in very early prophase stages (Jackman et al., 2003) , showed minimal staining in ICRF-193-arrested cells ( Figure 3C and our unpublished results). This premitotic cyclin B1/p21 nuclear accumulation is not limited to cells treated with ICRF-193 as it could be readily observed in NHF treated with bleomycine or exposed to γ-rays (Suppl. Figure 3A and C).
It represents thus most likely a general response to DNA damage in normal fibroblasts.
Induction of p21-cyclin B1-Cdk1 complexes after DNA damage
Given the striking nuclear co-localisation of p21 and cyclin B1, we sought to verify whether, under these experimental conditions, p21 associates significantly with cyclin B1
and Cdk1. We therefore compared p21 and cyclin B1 immunoprecipitates isolated from extracts of untreated cells and those exposed to ICRF-193 and bleomycin for 12 hours.
Prolonged exposure of NHF to these drugs induced a cell cycle exit that is accompanied with down-regulation of mitotic cyclins . The cell cycle profile of the cultures used in this experiment is shown in Figure 2A .
Western blot analysis of these immunoprecipitates shows that each drug treatment provokes a dramatic accumulation of cyclin B1-Cdk1-p21 complexes ( This, in turn, would block recruitment of cyclin B1-Cdk1 to the centrosome and its activation by Cdc25 family phosphatases, which are mostly cytoplasmic in G2 phase.
Alternatively, p21 could prevent directly Cdc25-dependent dephosphorylation of Cdk1 as shown for cyclin-Cdk2 complexes (Saha et al., 1997) . If this hypothesis is true, cyclin B1
would not accumulate in the nucleus of cells lacking p21 after treatment with genotoxic drugs and, consequently, activation of cyclin B1-Cdk1 at the centrosome would not be hampered.
Nuclear accumulation of cyclin B1 is p21-dependent
To check this hypothesis, we studied human fibroblasts expressing the HPV16-E6
oncogene (referred to as E6 cells), which contain very low amounts of p21 (see also Figure 5A and ref. Baus et al., 2003) . We have previously shown that in the presence of ICRF-193, E6 cells transiently arrest in G2 phase cells, but eventually enter mitosis with active cyclin B1-Cdk1 . We examined the localisation of cyclin B1 in synchronized E6 cells untreated (G2/M) or exposed to . In contrast to wild-type cells ( Figure 1A ), cyclin B1 failed to accumulate in the nucleus of E6 cells arrested in G2 phase. Instead, it was mostly localized in the cytoplasm but was readily detectable at the centrosomes ( Figure 3A and 3B). Most importantly, as determined by immunostaining with an anti-PS133 antibody (Jackman et al., 2003) , these centrosomal cyclin B1-Cdk1 complexes appeared to be active ( Figure 3C ). In contrast, no PS133 signal could be detected at the centrosomes of ICRF-193-arrested wild-type NHF.
Centrosomal staining with an anti-PS133 signal together with an elevated Mpm2 signal in drug-treated E6 cells led us to conclude that these cells were not truly arrested in G2 phase but were in fact undergoing early mitotic events ( Figure 3D ). This is in agreement with the observation that in drug-arrested E6 cells, cyclin B1-associated kinase activity, albeit weak in comparison to mitotic cells, is significantly higher than that of cyclin B1 complexes in G2-arrested wild-type NHF (Dulic et al., 1998; Passalaris et al., 1999; Baus et al., 2003) .
To eliminate the possible contribution of other p53 (or E6) targets, we studied cyclin B1 localization in response to DNA damage (ICRF-193, γ-irradiation) in asynchronously growing p21 null fibroblasts (Wei et al., 2001) . Unlike their wild-type counterparts (LF1), p21 -/-NHF failed to block pRb phosphorylation and efficiently inactivate cyclin B1-associated kinase activity in the presence of ICRF-193 ( Figure 4A,B) , thus confirming our earlier observation in E6 cells . As shown by Western blot analysis of cyclin B1 immunoprecipitates (Figure 4B ), cyclin B1 complexes from ICRF-193-treated wild-type cells contained increased levels of p21 as well as both unphoshorylated (isoform 1) and hyperphosphorylated (isoform 3) Cdk1. Although in ICRF-193-treated p21 -/-NHF most of cyclin B1 was associated with hyperphosphorylated Cdk1 (isoform 3), elevated cyclin B1-associated kinase activity further confirmed that p21 also participates in inactivation of Cdk1.
In addition, immunofluorescence experiments clearly showed that in p21 -/-NHF cyclin B1 remained in the cytoplasm both after the treatment with ICRF-193 and γ-rays ( Figure 4C ). Moreover, like in E6 cells, in most of the p21 -/-cells cyclin B1 was strongly localized at the centrosome and cells undergoing mitosis could be readily observed.
Counterstaining with anti-γ-H2AX antibody revealed numerous DNA-damage-resulting foci that were present even in mitotic cells ( Figure 4B ).
Taken together these results strongly imply that p21 exerts a direct role in negatively regulating mitotic entry by interfering with recruitment of active cyclin B1-Cdk1 complexes to the centrosome. They are also consistent with the possibility that, by associating to p21, cyclin B1-Cdk1 could not be activated in the cytoplasm or in the nucleus.
Cyclin B1 nuclear sequestration increases in cells with high p21 levels
To further strengthen our hypothesis that, in response to genotoxic stress, nuclear sequestration of cyclin B1-Cdk1 by p21 impedes its activation, we investigated cyclin B1 localization in NHF containing high amounts of endogenous p21. To this end we used NHF expressing HPV16-E7 oncoprotein (E7 cells, described in ; Figure 5A ) that degrades pocket proteins of the retinoblastoma family (Munger et al., 2001) . Despite high p21 levels ( Figure 5A ), E7 cells proliferate well since this inhibitor is virtually absent from S and M phase cells ( Figure 5C and our unpublished results). Thus, the E7 cell model provides a clear advantage in comparison to cell lines that ectopically overexpress p21, since the latter cannot proliferate (Smits et al., 2000) . Moreover, we have recently shown that in E7 cells p21 is fully functional, since after treatment with genotoxic agents, G2 arrest and Cdk inactivation correlated with a strong association of p21 with cyclin-Cdk complexes , Figure 5A ).
In most untreated E7 cells, the centrosomal and nuclear localisation of cyclin B1 correlated well with mitotic entry as monitored by the DNA condensation pattern and increasing Mpm2 signal ( Figure 5B ). In E7 cultures one could also observe some cells Moreover, these cells were arrested in G2 phase as documented by Mpm2 staining (
Figure 5B), lack of DNA condensation and absence of cyclin B1 at unseparated centrosomes (our unpublished results). Importantly, cyclin B1 nuclear accumulation closely correlated with a dramatically elevated p21 signal ( Figure 5C ).
p21 binds to inactive cyclin B1-Cdk1 complexes
This exceptionally strong nuclear co-localization of cyclin B1 and p21 in G2 arrested E7 cells allowed us to test whether cyclin B1 nuclear accumulation is concomitant to binding to p21. We firstly compared cyclin B1 immunoprecipitates isolated from E7 cells to those from E6 cells, which have low p21 levels . In both E6 and E7 cells, the presence of ICRF-193 induced strong accumulation of cyclin B1-Cdk1 complexes but, in comparison to drug-treated E6 cells, in E7 cells cyclin B1-associated kinase activity was extremely low ( Figure 6A) . As judged by the results shown in Figure 6A and B, the low kinase activity of these complexes in E7 cells could be attributed to their increasing association with p21.
To determine more precisely the proportion of cyclin B1-Cdk1 complexes in ICRF-193-arrested E7 cells that is actually bound to p21, we compared cyclin B1
immunoprecipitates isolated before and after removal of all p21-associated proteins by immunodepletion. As shown in Figure 6B and C, in drug-treated cells, the vast majority of cyclin B1-Cdk1 complexes was bound to and thus most likely kept inactive by p21. This is also the first evidence showing that cyclin B1-Cdk1 can massively associate with normally regulated p21 even in the absence of ectopic p21 overexpression. Furthermore, together with the previous observation that cyclin B1 and p21 co-localize in some cells even in untreated E7 cultures (
Figure 5B), these results provide an explanation for the low cyclin B1-associated kinase activity observed in these cells ( Figure 6A ).
In addition, p21 immunodepletion experiments allowed us to identify the specific cyclin B1-Cdk1 complexes that are targeted by p21 and thus presumably retained in the nucleus. As shown in Figure 6C , p21-bound cyclin B1 complexes contain both hyperphosphorylated (isoform 3) and hypo-phosphorylated (isoform 1) Cdk1. Isoform 3 is phosphorylated on Thr161 by CAK (Cdk-activating kinase) and on Thr14 and on Tyr15 by
Myt1 and Wee1/Mik1 kinases, respectively (Porter and Donoghue, 2003) . Its accumulation in inactive cyclin B1 complexes implies that p21 blocks, directly or indirectly by nuclear sequestration, dephosphorylation of Cdk1 by Cdc25 (see also Figure 2B ). Isoform 1 would correspond, a priori, to an active enzyme (arrow in Figure 6D ) whose Thr14 and Tyr15 residues are de-phosphorylated by Cdc25 while Thr161 remains phosphorylated (Morgan, 1995) . However, our results suggest that this fastest migrating isoform corresponds mainly to un-phosphorylated Cdk1 since it is only weakly phosphorylated on Thr161 in comparison to E6 cells, where this isoform is much less abundant ( Figure 6E) . Note that the intermediate and partially active Thr14-dephosphorylated isoform 2 of Cdk1 (Borgne and Meijer, 1996) is largely absent in inactive cyclin B1 complexes isolated from G2-arrested cells (see Figure 2A) . Although the complexes between cyclin B1 and unphosphorylated Cdk1 have not been described in vivo (Ducommun et al., 1991) , they are probably stabilised in the nucleus in the presence of elevated p21 levels (cf. (Smits et al., 2000; Baus et al., 2003) . Altogether, these results further support our hypothesis that, by binding to cyclin B1-Cdk1 complexes, p21 causes their nuclear retention and blocks the activation of Cdk1 at different stages.
P21 blocks activation of cyclin B1-Cdk1 by Cdc25
While inhibition of CAK-dependent phosphorylation of different Cdks by p21 is quite well documented (Aprelikova et al., 1995; Kaldis et al., 1998) , only one report shows that p21 could interfere with activation of cyclin-Cdk2 by Cdc25 in vitro (Saha et al., 1997) . Our results showing that p21 associates with hyperphosphorylated Cdk1 (Figures 2 and 6) raised a possibility that this inhibitor could also prevent activation of cyclin B1-Cdk1 by Cdc25-dependent dephosphorylation. To explore this possibility, we exposed cyclin B1
immunoprecipitates isolated from different cells arrested in S or G2 phases to recombinant Cdc25B and analysed them subsequently for Cdk1 phosphorylation status and associated histone H1 kinase activity (Figure 7) . Indeed, Cdc25B could readily activate cyclin B1-
Cdk1 complexes isolated from p21-deficient cells such as HeLa cells arrested in S phase
by thymidine block ( Figure 7A, lanes 1,2) , E6-expressing NHF arrested in G2 phase by 4) or in S/G2 by bleomycine (lanes 5,6). Note a diminution of isoform 3
and an increase of isoforms 1 and 2 in Cdc25-treated immunoprecipitates.
In contrast, Cdc25B was unable to dephosphorylate Cdk1 isoform 3 and activate cyclin B1 immuno-complexes isolated from ICRF-treated E7-expressing fibroblasts ( Figure 7B , lanes 1,2) and p21-bound cyclin B1-Cdk1 complexes isolated from ICRF-treated wildtype NHF cultures (lanes 5-8). On the other hand, under these experimental conditions Cdc25B could readily activate cyclin B1-Cdk1 from untreated wild-type NHF (WT-CT), which lacked p21 (lanes 3,4). These results point toward a novel way by which p21 could sustain G2 arrest and prevent efficiently (and permanently) mitotic progression.
Discussion
The results presented in this paper describe the molecular mechanisms underlying long-term inactivation of cyclin B1-Cdk1 in response to DNA damage in normal human fibroblasts (NHF). The activity of cyclin B1-Cdk1, which plays a crucial role in controlling the initiation and progression of mitosis, is tightly regulated at multiple levels. In cycling cells, cyclin B1-Cdk1 complexes are kept inactive during S and G2 phases by inhibitory phosphorylations on Cdk1 at Thr14 and Tyr15 (by Myt1 and Wee1 kinases) and they are retained in the cytoplasm due to an active nuclear export (Hagting et al., 1998; Yang et al., 1998) . The onset of prophase correlates with dephosphorylation of Cdk1 by Cdc25 family phosphatases, phosphorylation of cyclin B1 and a rapid nuclear accumulation of active cyclin B1-Cdk1 (rev. in (Porter and Donoghue, 2003) . In the presence of DNA damage, activation of cyclin B1-Cdk1 and mitotic entry are initially blocked by Chk1/2-dependent inhibition of Cdc25 members, an event that does not require functional p53 (Taylor and Stark, 2001 ). G2 arrest is further assured by nuclear exclusion of cyclin B1-Cdk1 (Jin et al., 1998; Yang et al., 1998; Deming et al., 2001; Yang et al., 2001) , which is achieved by binding to the adaptor protein 14-3-3σ , a transcriptional target of p53 (Hermeking et al., 1997; Chan et al., 1999; van Hemert et al., 2001) . However, since 14-3-3σ is mainly expressed in epithelial cells (Hermeking et al., 1997) , it is likely that alternative mechanisms may contribute to sustain cyclin B1-Cdk1 inactivation in other cell types.
Another p53 target, p21 Waf1/Cip1 (p21), does not appear to control directly the initiation of DNA damage-induced G2 arrest but accumulating evidence suggests that this Cdk inhibitor plays a major role in its maintenance (Bunz et al., 1998; Ohi and Gould, 1999; Taylor and Stark, 2001) . We have recently shown that this could be due to its ability to block the Cdk-dependent phosphorylation of pocket proteins .
Interestingly, in spite of its strong association with cyclin A-Cdk1 , available data suggest that cyclin B1-Cdk1 complexes are not an important target of p21 (Winters et al., 1998; Passalaris et al., 1999; Flatt et al., 2000; Smits et al., 2000; Deming et al., 2001 ).
However, in this paper we present evidence that in normal human fibroblasts (NHF) p21 actually could play a direct role in preventing activation of cyclin B1-Cdk1 in response to genotoxic stress. We show that in the presence of non-repairable DNA damage occurring in S and G2 phases NHF accumulate cyclin B1 in the nucleus without apparent signs of mitotic events. Moreover, our results suggest that this nuclear retention of inactive cyclin B1-Cdk1 complexes is caused by binding to p21. This observation gains its importance in view of the recent reports showing that in proliferating cells cyclin B1-Cdk1 is already activated at the centrosomes (Hirota et al., 2003; Jackman et al., 2003) , implying that some early mitotic events could be initiated while cyclin B1 is still mainly in the cytoplasm (Pines and Rieder, 2001) . In light of the latter observation, it may seem contradictory that cyclin B1 could localize in the nucleus without initiation of mitosis. This apparent contradiction could be resolved by our results showing that, by binding to and sequestering cyclin B1-Cdk1 in the nucleus, p21 inhibits their activation which takes place either in the cytoplasm/centrosome (De Souza et al., 2000) or/and in the nucleus. In this way, the cells expressing p21 could efficiently block initiation of early mitotic events (Figure 8 ).
Biochemical analysis of cyclin B1-Cdk1 complexes isolated from arrested cells supports entirely the hypothesis that p21 interferes with both CAK-mediated phosphorylation of Thr161 and with Cdc25-mediated dephosphorylation of Thr14 and Tyr15 (Figure 7 and cf. . Moreover, our results showing that p21 directly blocks the latter event are in agreement with an earlier work indicating that Cdc25A-cyclinCdk2 association is inhibited by p21 (Saha et al., 1997) .
The critical role of p21 in nuclear sequestration and blocking activation of cyclin B1-Cdk1 is underscored by our results showing that exposure of p21-deficient or null fibroblasts to genotoxic stress does not induce nuclear retention of cyclin B1. As a consequence, these cells fail to prevent efficiently centrosomal recruitment and activation of cyclin B1-Cdk1 and are unable to undergo a permanent G2 arrest (cf. (Passalaris et al., 1999; Baus et al., 2003) . Conversely, in HPV16-E7-expressing fibroblasts containing high endogenous levels of p21, after exposure to genotoxic drugs virtually all cyclin B1-Cdk1 complexes are associated with p21 and remain inactive in the nucleus. Although previous work indicated that, in carcinoma cells with inducible p53 or p21 levels, DNA damage could also lead to nuclear accumulation of cyclin B1 (Winters et al., 1998; Smits et al., 2000) , these experiments failed to show a significant association between p21 and cyclin B1-Cdk1. Therefore, this is the first report showing that, in response to a genotoxic insult, endogenous p21 could massively bind to cyclin B1-Cdk1. Our previous results, obtained in synchronized NHF, implied that premitotic nuclear accumulation of cyclin B1 and p21 could be an integral part of G2/M progression (Dulic et al., 1998) . Since this event is rarely observed in asynchronously proliferating early-passage wild-type NHF (F.B. and V.D., unpublished data), we assume that its occurrence has been provoked by increased levels of p21 induced by hydroxyurea or aphidicolin used in the synchronization protocol.
The question is why, in addition to Cdc25 pathway, the cells would need also p21 to prevent cyclin B1-Cdk1 activation? One possibility is that, by (permanently?) locking cyclin B1-Cdk1 in non-activable complexes (bound for degradation?), normal fibroblasts take advantage of an additional level of security thereby assuring the irreversibility of the G2 arrest (Figure 8) . As mentioned before, in other cell types a stable G2 arrest was proposed to be achieved by a 14-3-3σ-mediated nuclear exclusion of cyclin B1-Cdk1 complexes (Jin et al., 1998; Toyoshima et al., 1998; Chan et al., 1999) . Our results, which were obtained in normal fibroblasts with a priori intact cell cycle control pathways, indicate that p21-dependent nuclear sequestration of cyclin B1-Cdk1 may have evolved as an alternative safeguard mechanism to block permanently mitotic entry. The respective contribution of p21 and 14-3-3σ-dependent mechanisms to this block should be further evaluated in normal cell types of different origin.
In conclusion, we propose that p21 exerts a dual role in mediating stress-induced cell cycle arrest and irreversible exit before mitosis (Figure 8) . Its first role would be to stably prevent activation of mitotic cyclin-Cdk complexes -by directly inactivating cyclin ACdk1/2, by maintaining the inactive state of cyclin B1-Cdk1 by nuclear sequestration and by inhibiting CAK-and Cdc25-dependent activation. Indeed, it has been shown that p21 interferes with activation of cyclin A-Cdk2 (Aprelikova et al., 1995; Saha et al., 1997; Kaldis et al., 1998) . The second role of p21 would be to block inactivating phosphorylations of pocket proteins by Cdks (Figure 8 ). Subsequent accumulation of active pocket proteins would drive permanent cell cycle exit, at least partially by sequestering E2F factors playing a role in the G2/M transition Baus et al., 2003) . Thus, in addition to its well-established role in the G1/S cell cycle checkpoint, p21 appears to be a crucial element for G2 arrest, the ultimate barrier to the entry of cells with damaged chromosomes into mitosis. In response to DNA damage G2 arrest is initiated by Chk1/2-dependent inactivation of Cdc25 family phosphatases (Cdc 25A,B,C) thus preventing activation of cyclin B1-Cdk1.
The maintenance of G2 arrest is assured by p21-dependent inactivation of mitotic Cdks 
